10 news items
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
3 Jun 24
such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
BTBT
INBS
MGOL
24 May 24
earnings surprise. CEO and CFO will present at a virtual conference on May 30, offering investors access to webcast materials on the company's site
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
therapies from materials collected from a single donor. Thus, our potential to treat a significant number of cancer patients with SNK02 is remarkably high
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
NKGN
16 May 24
such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those
4ltm9rdnn5oy3iq1jc5n6vwtqstidv3lopyak6o ufvh7tu
NKGN
25 Apr 24
control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include
5kwq9w99g7u2kmiids3s9i1rtgdhanpgd5m0es3hdarohjx7grt7
NKGN
24 Apr 24
of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements
kvatmvhdg5hpk7tfy1yaz
NKGN
11 Apr 24
are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed
sguftilj7cm g9ma4kjjg68uszwiqelktnn6wmsze835bq8t2x4
NKGN
25 Mar 24
/duration was initiated in the U.S. in 2023.A copy of the abstract and presentation materials will be available on the Scientific
03ysaagcihfr4jzt13vlfkv27zuqkapdxtd6nhi
NKGN
25 Mar 24
. in 2023. A copy of the abstract and presentation materials will be available on the Scientific Publications page
- Prev
- 1
- Next